Kintara Q2 net loss $3.5M; cash $4.9M; VAL-083 gets orphan status for DIPG

TuHURA Biosciences, Inc./NV

Net loss of $3.5M vs $5.9M YoY; diluted EPS -$2.10 vs -$6.07.
Cash and equivalents $4.9M at Dec 31, 2022, down from $11.8M at June 30.
FDA granted Orphan Drug Designation for VAL-083 in DIPG; Fast Track for REM-001 in CMBC.
REM-001 program paused to conserve cash, expected savings of ~$3.0M through CY2023.
Regained Nasdaq minimum bid price compliance after 1-for-50 reverse stock split.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TuHURA Biosciences, Inc./NV reported fiscal year 2023 second quarter ended December 31, 2022 results: net income net loss of approximately $3.5 million, or $2.10 per share, EPS $2.10 per share.

Period: fiscal year 2023 second quarter ended December 31, 2022
Net income: net loss of approximately $3.5 million, or $2.10 per share
EPS: $2.10 per share
Result: reported results

Exact text from the filing

For the three months ended December 31, 2022, Kintara reported a net loss of approximately $3.5 million, or $2.10 per share, compared to a net loss of approximately $5.9 million, or $6.07 per share, for the three months ended December 31, 2021.

View on SEC.gov

9 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-002808

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.